BioProtect

Tzur Yigal, Israel · Founded 2004 · Acquired/Merged (Operating Subsidiary)

Developer of a pro-space balloon system designed to safely and temporarily separate the rectum during prostate cancer radiation therapy. BioProtect is based in Tzur Yigal, Israel and was founded in 2004. Its last known valuation is $200 million (Jan 2026). It has raised $67.9 million.

Last price · $/share
—
Implied valuation
$200.0M
Total raised
$67.9M
Last round
—
What is BioProtect worth?
$200.0Mlast known valuation
Free account
More of BioProtect with a free account
  • ·The complete investor list: 21 names
  • ·Watch BioProtect: the Monday email on marks, rounds and moves
Create free account
No card required

Membership and data by Private Market View

BioProtect funding history

No rounds on record

No funding rounds for BioProtect are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.

Pro members can request priority coverage with a 48-hour turnaround.

BioProtect valuation

BioProtect's last known valuation is $200 million, from Jan 2026. The figure stands until a priced round, a secondary trade or an institutional fund mark prices the stock again.

How BioProtect's valuation is determined

Private company valuations aren’t quoted on an exchange — they’re established in moments: a priced funding round sets a post-money valuation, secondary trades print at a price per share, and SEC-registered funds holding the stock report fair-value marks in their N-PORT filings.

For BioProtect, too few pricing signals exist to publish a composite mark; the figures above reflect the most recent observed valuation event. Full methodology →

Frequently asked about BioProtect

What is BioProtect worth?
BioProtect's last known valuation is $200.0M.
How much has BioProtect raised?
BioProtect has raised $67.9M in total funding across its recorded rounds.